Is Now The Right Time To Buy GlaxoSmithKline plc?

GlaxoSmithKline plc (LON:GSK) shareholders have had a rocky ride this year, but the outlook is improving, says Roland Head.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

gskGlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) has had to endure nearly as much bad press as British Gas owner Centrica this year, thanks to a major corruption scandal that has decimated sales in China, and created a storm of bad publicity for the firm.

In addition to this, the pharma giant’s results have been pretty lacklustre over the last 12 months, so it’s no surprise that Glaxo’s share price has underperformed the wider market and fallen by 10%, so far this year.

However, as billionaire Warren Buffett once said, “you pay a very high price in the stock market for a cheery consensus”. Given all of the bad news which has rocked Glaxo this year, could now be the ideal time to buy?

Should you invest £1,000 in Kingfisher Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Kingfisher Plc made the list?

See the 6 stocks

Valuation

Let’s start with the basics: how is Glaxo valued against its past performance, and against current forecasts for 2014 and 2015?

P/E ratio Current value
P/E using 5-year average adjusted earnings per share 14.3
2-year average forecast P/E 14.8

Source: Company reports, consensus forecasts

Glaxo’s forecast valuation is broadly in line with its historical earnings, suggesting that today’s share price is fair, if not an outright bargain.

However, the pharma giant’s yield could tip the bargain for many investors, as few companies offer a 5.6% prospective yield, that’s backed by a strong record of free cash flow cover.

In my view, Glaxo is a good buy for income, with additional long-term capital gains potential.

What about the fundamentals?

In the long-term, a company needs to deliver long-term sales and profit growth, in order to support its share price and fund shareholder returns.

How does Glaxo shape up on this basis?

5-year compound average growth rate GlaxoSmithKline
Sales -1.4%
Pre-tax profit -3.3%
Adjusted earnings per  share -1.7%
Dividend 5.0%

Source: Company reports

The impact of the ‘patent cliff’ is clear when you look at Glaxo’s results over a five-year timeframe. While the company’s operating margin has remained strong, averaging 25% since 2009, Glaxo has failed to generate either sales or profit growth.

However, the firm’s high margins and strong cash flow generation has mean that it has been able to continue rewarding shareholders, with dividend payments up by an average of 5% per year over the last five years.

Where’s Glaxo going?

Glaxo’s chief executive, Sir Andrew Witty, makes no secret of the fact that the pharmaceutical firm is going through a significant period of change.

This process won’t be quick, but I believe the longer-term benefits from Glaxo’s multi-billion dollar consumer healthcare and vaccine deal with Novartis could be considerable — plus there’s the tempting prospect that the consumer healthcare business could be spun-off into a separate company, generating a windfall for shareholders.

Should you buy Kingfisher Plc shares today?

Before you decide, please take a moment to review this first.

Because my colleague Mark Rogers – The Motley Fool UK’s Director of Investing – has released this special report.

It’s called ‘5 Stocks for Trying to Build Wealth After 50’.

And it’s yours, free.

Of course, the decade ahead looks hazardous. What with inflation recently hitting 40-year highs, a ‘cost of living crisis’ and threat of a new Cold War, knowing where to invest has never been trickier.

And yet, despite the UK stock market recently hitting a new all-time high, Mark and his team think many shares still trade at a substantial discount, offering savvy investors plenty of potential opportunities to strike.

That’s why now could be an ideal time to secure this valuable investment research.

Mark’s ‘Foolish’ analysts have scoured the markets low and high.

This special report reveals 5 of his favourite long-term ‘Buys’.

Please, don’t make any big decisions before seeing them.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares in GlaxoSmithKline. The Motley Fool recommends GlaxoSmithKline.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »